Compare with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PIRAMAL ENTERPRISES ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x - 18.3 - View Chart
P/BV x 6.5 1.2 559.7% View Chart
Dividend Yield % 0.7 1.5 43.7%  

Financials

 ALKEM LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PIRAMAL ENTERPRISES
Mar-19
ALKEM LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,5893,303 48.1%   
Low Rs1,2321,797 68.6%   
Sales per share (Unadj.) Rs417.5716.5 58.3%  
Earnings per share (Unadj.) Rs56.379.7 70.6%  
Cash flow per share (Unadj.) Rs64.7107.9 60.0%  
Dividends per share (Unadj.) Rs12.7028.00 45.4%  
Dividend yield (eoy) %0.91.1 82.0%  
Book value per share (Unadj.) Rs292.91,477.5 19.8%  
Shares outstanding (eoy) m119.57184.45 64.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.43.6 94.9%   
Avg P/E ratio x25.132.0 78.3%  
P/CF ratio (eoy) x21.823.6 92.3%  
Price / Book Value ratio x4.81.7 279.0%  
Dividend payout %22.635.1 64.2%   
Avg Mkt Cap Rs m168,653470,292 35.9%   
No. of employees `000NA7.8 0.0%   
Total wages/salary Rs m9,17122,504 40.8%   
Avg. sales/employee Rs ThNM16,899.4-  
Avg. wages/employee Rs ThNM2,877.7-  
Avg. net profit/employee Rs ThNM1,879.9-  
INCOME DATA
Net Sales Rs m49,915132,153 37.8%  
Other income Rs m1,6453,128 52.6%   
Total revenues Rs m51,561135,281 38.1%   
Gross profit Rs m8,48266,290 12.8%  
Depreciation Rs m1,0065,202 19.3%   
Interest Rs m67144,097 1.5%   
Profit before tax Rs m8,45120,119 42.0%   
Minority Interest Rs m-1143,194 -3.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6068,611 18.6%   
Profit after tax Rs m6,73114,701 45.8%  
Gross profit margin %17.050.2 33.9%  
Effective tax rate %19.042.8 44.4%   
Net profit margin %13.511.1 121.2%  
BALANCE SHEET DATA
Current assets Rs m27,062122,742 22.0%   
Current liabilities Rs m15,324310,810 4.9%   
Net working cap to sales %23.5-142.3 -16.5%  
Current ratio x1.80.4 447.2%  
Inventory Days Days6723 288.3%  
Debtors Days Days4139 106.3%  
Net fixed assets Rs m12,610116,904 10.8%   
Share capital Rs m239369 64.8%   
"Free" reserves Rs m34,490272,161 12.7%   
Net worth Rs m35,027272,530 12.9%   
Long term debt Rs m1,212270,196 0.4%   
Total assets Rs m54,387856,261 6.4%  
Interest coverage x13.61.5 934.1%   
Debt to equity ratio x01.0 3.5%  
Sales to assets ratio x0.90.2 594.7%   
Return on assets %13.66.9 198.2%  
Return on equity %19.25.4 356.3%  
Return on capital %24.912.4 200.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56315,200 43.2%   
Fx outflow Rs m3,0124,889 61.6%   
Net fx Rs m3,55210,312 34.4%   
CASH FLOW
From Operations Rs m7,259-115,975 -6.3%  
From Investments Rs m1,864-8,265 -22.6%  
From Financial Activity Rs m-9,273107,525 -8.6%  
Net Cashflow Rs m-150-16,650 0.9%  

Share Holding

Indian Promoters % 66.9 52.9 126.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.0 827.5%  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 16.5 -  
Shareholders   68,381 93,274 73.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PLETHICO PHARMA  WOCKHARDT  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 18, 2019 12:53 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS